Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Sanofi

Status and phase

Completed

Phase 3

Conditions

Japanese Encephalitis

Encephalitis

Treatments

Biological: 0.9% Saline

Biological: ChimeriVax-JE, Japanese Encephalitis vaccine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00314132

H-040-010

Details and patient eligibility

About

The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.

Enrollment

2,004 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Informed consent obtained from the subject.
Aged 18 years or above at screening.
In good general health
Subject available for the study duration
For female subjects (of child bearing potential) a negative pregnancy tests at Screening and Day 0.

Exclusion criteria

A history of vaccination against or infection with JE.
Known or suspected immunodeficiency, use of immunosuppressive or antineoplastic drugs.
History of thymoma, thymic surgery (removal) or myasthenia gravis.
Clinically significant abnormalities on laboratory assessment
Anaphylaxis or other serious adverse reactions characterised by urticaria or angioedema to foods, Hymenoptera (bee family) stings, or drugs including vaccines).
Transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within six months of the Screening Visit or up to Day 30.
Administration of another vaccine or antiviral within 30 days preceding the Screening visit or up to Day 30.
Physical examination indicating any clinically significant medical condition.
Oral temperature >38°C (100.4°F) or acute illness within 3 days prior to inoculation.
Intention to travel out of the area for an extended period that may affect the subjects ability to attend clinic visits prior to the study visit up to Day 30.
Seropositive to hepatitis C virus (HCV) or HIV or positive for Hepatitis B Surface Antigen.
Lactation or intended pregnancy in female subjects.
Excessive alcohol consumption, drug abuse, significant psychiatric illness.
A known or suspected physiological or structural condition that compromises the integrity of the blood-brain barrier (e.g. cerebrovascular disease, multiple sclerosis, trauma, infection, inflammation of the brain or meninges).
Participation in another clinical study within 30 days of the screening visit for this study.
Employee of the study site, Sponsor or Clinical Research Organization (CRO) involved with the management of the study.
Any other reasons, which in the investigator's opinion, makes the subject unsuitable to participate in the study.